Pfizer Inc (PFE)

31.63
0.17 0.54
NYSE : Health Care
Prev Close 31.46
Open 31.54
Day Low/High 31.36 / 31.73
52 Wk Low/High 28.25 / 37.39
Volume 18.98M
Avg Volume 24.69M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 195.04B
EPS 1.10
P/E Ratio 15.38
Div & Yield 1.20 (3.70%)

Latest News

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on...

LYRICA® (pregabalin) Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

LYRICA® (pregabalin) Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to...

Omnicell's Performance Center Integrates With Hospira's Infusion Pump Software

Omnicell's Performance Center Integrates With Hospira's Infusion Pump Software

New Interoperability Is Designed to Streamline Clinical Workflow

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

Pfizer Announces Positive Top-Line Results From The Pivotal Comparative REFLECTIONS B3271002 Study For PF-05280014, A Potential Biosimilar To Herceptin®1 (trastuzumab)

Pfizer Announces Positive Top-Line Results From The Pivotal Comparative REFLECTIONS B3271002 Study For PF-05280014, A Potential Biosimilar To Herceptin®1 (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint.

In Case You Missed It Tuesday: Self-Driving Cars, Soy, Slumping Commodities Take Markets for a Ride

In Case You Missed It Tuesday: Self-Driving Cars, Soy, Slumping Commodities Take Markets for a Ride

A Brazilian plane crash near Medellín on Monday included 21 journalists, among the largest number of media personnel to die in any one incident.

Closing Bell: Crude Tumbles to Two-Week Low; U.S. Stocks Inch Higher

Closing Bell: Crude Tumbles to Two-Week Low; U.S. Stocks Inch Higher

Stocks climbed as evidence of an economy on the mend overshadowed a slump in crude oil prices.

Stocks Stop Short of Records as Crude Collapses to Two-Week Low

Stocks Stop Short of Records as Crude Collapses to Two-Week Low

Wall Street ended just shy of records on Tuesday as a collapse in crude oil prices limited upward momentum.

Pfizer Upgraded at Barclays

Pfizer Upgraded at Barclays

Shares of Pfizer were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight

Stocks Climb as Solid U.S. Economic Growth Overshadows Oil's Tumble

Stocks Climb as Solid U.S. Economic Growth Overshadows Oil's Tumble

Stocks climb on Tuesday as evidence of an economy on the mend overshadows a slump in crude oil prices.

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Market should still be able to breathe once central-bank prop is removed.

Pfizer (PFE) Stock Rating Upgraded at Barclays

Pfizer (PFE) Stock Rating Upgraded at Barclays

Pfizer's (PFE) stock rating at Barclays was upgraded to 'overweight' earlier today.

S&P 500 Shakes Off Oil Slump to Post Gains

S&P 500 Shakes Off Oil Slump to Post Gains

Stocks move higher on Tuesday morning, shaking off earlier losses driven by a slump in crude oil.

Pfizer: Be Happy With the Dividend for Now

Pfizer: Be Happy With the Dividend for Now

A new period of accumulation and sideways price action is likely needed before any upside movess.

Stock Futures Turn Mixed as U.S. Economy Grows, Oil Prices Slump

Stock Futures Turn Mixed as U.S. Economy Grows, Oil Prices Slump

Stock futures hold higher on Tuesday morning, unperturbed by a sharp decline in crude oil prices, as the U.S. economy grows at a faster-than-expected pace over the third quarter.

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Merck Raises Dividend

We favor AbbVie and Pfizer in pharma sector.

Anthony J. Maddaluna, Executive Vice President And President Of Pfizer Global Supply To Retire

Anthony J. Maddaluna, Executive Vice President And President Of Pfizer Global Supply To Retire

Pfizer Inc. (NYSE:PFE) today announced that Anthony J.

Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

Pfizer Inc. (NYSE:PFE) (the " Company") today announced the expiration and results of the previously announced tender offer (the " Tender Offer") to purchase for cash any and all of its outstanding 6.

Pfizer Announces Pricing Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

Pfizer Announces Pricing Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

Pfizer Inc. (NYSE:PFE) (the " Company") today announced the pricing of the previously announced tender offer (the " Tender Offer") to purchase for cash any and all of its outstanding 6.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer's IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer's IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that detailed results from the Phase 3 PALOMA-2 trial were published in The New England Journal of Medicine.

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #13 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #260 spot.

Pfizer Announces Results From Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) For Psoriatic Arthritis

Pfizer Announces Results From Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) For Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today that new results from the Phase 3 Oral Psoriatic Arthritis Tria L (OPAL) studies, Broaden and Beyond, will be presented at the 2016 ACR/ARHP Annual Meeting (November 11-16,...

Pfizer Prices $6,000,000,000 Debt Offering

Pfizer Prices $6,000,000,000 Debt Offering

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of five tranches of notes: $1,000,000,000 aggregate principal amount of 1.